What is Artiva?
Founded in 2019 and headquartered in San Diego, California, Artiva Biotherapeutics is a clinical-stage biotechnology firm dedicated to the development of off-the-shelf, allogeneic Natural Killer (NK) cell therapies. The company's platform is engineered to address the limitations of current autologous cell therapies, offering a scalable and accessible alternative for the treatment of hematologic cancers and solid tumors. By focusing on the molecular basis of disease, Artiva aims to redefine the standard of care in oncology through innovative biological discovery and rigorous clinical execution.
How much funding has Artiva raised?
Artiva has raised a total of $198M across 2 funding rounds:
Series A
$78M
Series B
$120M
Series A (2020): $78M with participation from 5AM Ventures, MEDIVATE PARTNERS LLC, GC LabCell, venBio Partners LLC, and RA Capital Management LP
Series B (2021): $120M led by Franklin Templeton, Venrock Healthcare Capital Partners, Acuta Capital Partners, Cormorant Asset Management, and EcoR1 Capital
Key Investors in Artiva
Franklin Templeton
A global investment management organization providing specialized expertise across multiple asset classes, including venture capital and alternative investments for institutional and private clients.
Cormorant Asset Management
A prominent life sciences investment firm focused on fundamental scientific principles to support innovative companies within the biotech and allied sectors.
EcoR1 Capital
A San Francisco-based investment fund dedicated to the biotech sector, specializing in long-term partnerships with entrepreneurs advancing therapeutic innovation.
What's next for Artiva?
With the successful completion of its major enterprise-level funding rounds, Artiva is well-positioned to transition its lead candidates through critical clinical milestones. The strategic allocation of capital will likely prioritize the expansion of its manufacturing capabilities and the acceleration of its pipeline, which remains central to its long-term value proposition. As the biotech sector continues to prioritize off-the-shelf therapeutic modalities, Artiva's focus on allogeneic NK cell technology places it at the forefront of a significant shift in cancer treatment paradigms. Future growth will depend on the company's ability to maintain its scientific momentum while navigating the complex regulatory and commercial landscapes inherent in the development of novel cell-based medicines.
See full Artiva company page
